There are two Trials that they are testing on Sickle Cell patients, look them up on Google for more information about these trials, also you can directly contact the investigators by using the phone number or websit provided.

Trial 1:A Phase II Pharmacodynamic Investigation of the Efficacy of Vorinostat to Induce Fetal Hemoglobin in Adults With Severe Sickle Cell Disease Who Have Failed Prior Therapy

Dana-Farber Cancer Institute
Brigham and Women's Hospital
Children's Hospital Boston
Merck
Investigators
Principal Investigator: Maureen Okam, MD, MPH Brigham and Women's Hospital
Responsible Party: Brigham and Women's Hospital ( Maureen Okam, MD, MPH )
Study ID Numbers: 09-237
Study First Received: October 20, 2009
Contact: Maureen Okam, MD, MPH 617-732-5048
Contact: Ainsley Ross 617-732-8537

For more information you can go to http://clinicaltrials.gov/ct2/show/NCT01000155




Trial 2:

A Randomized, Blinded, Placebo-controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK 1001 in Subjects with Sickle Cell Disease

HemaQuest Pharmaceuticals Inc.
Study Director: Susan Perrine, M.D. HemaQuest Pharmaceuticals
Responsible Party: HemaQuest Pharmaceuticals, Inc. ( Susan Perrine, M.D. )
Study ID Numbers: HQP 2008-004
Study First Received: February 11, 2009
For information about this trial email: info@hemaquest.com.